For media inquiries, please contact Lise Bram, ADAA Deputy Executive Director: email@example.com
ADAA Announces #ADAA2021Virtual Conference - September 22, 2020
KidGuard Grant Awarded to ADAA - November 15, 2018
ADAA Statement on PTSD, Panic, and Sexual Assault - September 26, 2018
ADAA Welcomes Luana Marques, PhD as President-Elect - April 13, 2018
ADAA Has Been Nominated for the 2018 Change Maker Award! - March 9, 2018
A Message from the ADAA Board - January 10, 2018
ADAA Welcomes Beth Salcedo, MD as New Board President - January 3, 2018
Hope and Grace Fund Grant Awarded to ADAA - October 27, 2017
ADAA 2020 Conference News - Medscape.com
The findings were scheduled to be presented this month at the Anxiety and Depression Association of America (ADAA) Conference 2020, along with publication in the Journal of Affective Disorders. However, the ADAA conference was cancelled in the wake of the coronavirus pandemic.
- 04/07/2020 Worry, Anxiety Tied to Increased Inflammation, (ADAA Member) Megan Elizabeth Renna, PhD
- 04/06/2020 Rapid Response to PTSD Therapy May Predict Long-term Improvement
- 04/03/2020 IV Esketamine, Ketamine Equally Effective for Resistant Depression
- 03/31/2020 Mindfulness Interventions Linked to Cognitive Benefit, (ADAA member) Nur Hani Zainal, MS
ADAA 2019 Conference News
Disturbed Sleeps Derails Therapy for Complicated Grief, Medscape Medical News, April 9, 2019
Ketamine a Panacea for Resistant Depression? Not So Fast, Experts Say,Medscape Medical News, April 4, 2019
Self-Help App Helps Reduce Depression, Anxiety Symptoms, Healio, April 3, 2019
Songwriting May Hit the Right Therapeutic Note in PTSD, Medscape Medical News, April 3, 2019
Immunosuppressant May Extend Ketamine's Antidepressant Effects, Medscape Medical News, April 2, 2019
Patients with Anxiety, Mood Disorders Lack Self-compassion, Healio, April 1, 2019
Ketamine Improves Suicidal Ideation in Veterans with PTSD, MDD, Healio, April 1, 2019
Combination Therapy for PTSD Provides No Added Benefit, Medscape Medical News, April 1, 2019
Positive Pilot Phase 3 Data Position VistaGen’s PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder, VistaGen Therapeutics Press Release (research poster presented at #ADAA2019), April 1, 2019
#ADAA2019 Conference - Press Release - January 14, 2019
The Anxiety and Depression Association of America (ADAA) is delighted to announce that we have been awarded a 2018 Nonprofit grant from KidGuard.
Over the last several years, rates of childhood depression have continued to rise. Yet, information and awareness about childhood depression has not kept pace with this alarming trend. With increased exposure to social media, children are at greater risk of experiencing cyber-bullying and negative situations that can increase their anxiety, put them at risk for depression and in more severe cases, suicide. Funding from the KidGuard grant will help ADAA enhance our current educational content and mental health resources for children and teens. These resources include consumer webinars, child-friendly infographics, blog posts and educational videos covering topics such as childhood depression and anxiety, how to identify symptoms and where to find effective and suitable treatment options. Read the full press release.
SPRING, MD. (October 24, 2018) — Some of the most pressing mental health professionals face center around breaking cultural, racial, and socioeconomic barriers to anxiety and depression treatment. More than 1,400 international researchers and clinicians specializing in anxiety, depression, and related disorders will discuss these and other relevant topics when they convene March 28-31 at the Anxiety and Depression Association of America (ADAA) 2019 Conference at the Sheraton Grand Hotel in Chicago, IL. Read the full press release.
As clinicians, scientists, and professors who are experts in the fields of anxiety, depression,
and trauma, the recent media coverage of trauma and sexual assault have moved us to
comment, not on the particulars discussed, but on the potential impact on the patients to
whom we have committed our careers to help. Read the full statement.
This week we have lost Kate Spade and now Anthony Bourdain to suicide. The Board of the Anxiety and Depression Association of America (ADAA) offers our condolences to their families and to those touched by the lives of these two celebrated Americans.
Unfortunately, they are not alone. There will be 45,000 other deaths by suicide in this country within the year. One million worldwide. And that number, sadly, is growing. The CDC just released the results of a study this week showing that in a majority of US states, suicide has risen by almost 30% from 1999 to 2016. About half of those had a known mental health issue that was a likely contributor. Read more.
ADAA is pleased to announce that Luana Marques, PhD has been elected President-Elect of the ADAA Board of Directors and will assume the Board Presidency in January of 2020. Dr. Marques has been an active member of ADAA since 2008 and has served on the board since 2016. Dr. Marques is an ADAA Clinical Fellow, serves as the board liaison to the ADAA Annual Conference Committee, the Professional Education Committee, the PTSD Special Interest Group and the Multicultural Advances Special Interest Group. Read more.
We are proud to announce that the Anxiety and Depression Association of America has been chosen from among hundreds of organizations as one of five finalists for the 2018 Outstanding Organization Award from the Child Mind Institute!
The winner will be decided as a result of online voting which is open through March 23. We would really appreciate your support for us by voting for us today and spreading the word! Please note: one vote per email address per day may be entered. Read the full press release.
Anxiety disorders affect nearly 44 million adults and one in eight children in the United States. Although these disorders are highly treatable, only one-third of those struggling actually receive treatment. Without treatment, prolonged exposure to anxiety disorders can result in interference with daily functioning and can lead to depression, substance use, suicide attempts, and other co-occurring disorders.
Depressive disorders affect close to 19 million American adults. More than 50 percent of people diagnosed with depression are also co-diagnosed with an anxiety disorder. Coexisting anxiety and depression account for the most disabling mental health disorders in the United States. Read the full press release.
A Message from the ADAA Board - Year-End Reflections: Growth, Engagement and Impact - January 10, 2018
2017 has been a very busy year for ADAA! The San Francisco Annual Conference in April was a very successful highlight. With a record number of attendees (over 1,300) from across the United States and around the world attending more than 170 innovative sessions, listening to engaging keynotes and participating in special symposia, ADAA shone an important spotlight on behavioral medicine and its application to anxiety and depressive disorders. The 2018 Annual Conference will be held in DC this coming April and will focus on treatment-resistant anxiety and depression: challenges and opportunities. We look forward to another engaging 4 days of learning, sharing and connecting. ADAA is delighted to be offering conference attendees audio recordings of selected conference sessions (over 30 hours of programming, including up to 9 hours of CE). This is a great opportunity for attendees to enjoy enduring conference materials by offering the option to listen to sessions they might not have had time to attend live or to revisit their favorite sessions again, including Master Clinician sessions. Read the full statement.
ADAA is pleased to announce that Beth Salcedo, MD, has assumed the role of President of the ADAA Board of Directors (BOD) effective January 1, 2018. Dr. Salcedo will serve a two year term.
Dr. Salcedo succeeds Karen L. Cassiday, PhD, who served as ADAA BOD President from 2015-2017. Dr. Cassiday will now serve as Immediate Past Board Chair.
Dr. Salcedo has been an active member of ADAA since 2004, serving on the Executive Council as President Elect since 2016. Dr. Salcedo is an ADAA Clinical Fellow and co-chairs ADAA's Women's Special Interest Group. She is a psychiatrist with expertise in diagnostic assessment and psychopharmacologic management of anxiety and mood disorders in adults. Dr. Salcedo has been the medical director of The Ross Center since 2002, and has been with the center since 1997. She has also served as Assistant Clinical Professor, Psychiatry and Behavioral Sciences at the George Washington University College of Medicine and Health Sciences. Dr. Salcedo has been named in Washingtonian magazine's "Top Doctors" consistently since 2010. Read more.
ADAA is delighted to announce that we have received a grant from the hope & grace fund, a project of New Venture Fund in partnership with philosophy, inc.” The grant allows ADAA to launch an exciting new initiative “Turning a Laser-Focus on Women’s Issues in the Treatment of Anxiety, Depression and Related Disorders.”
Through this new project, ADAA will form a Women’s Special Interest Group to design women-focused programming for mental health professionals. It will also develop programming for its 2018 annual conference that focuses on evidence-based gender research and treatment options for women. Finally, ADAA will create women-focused webinars and outreach to educate the public about mental health treatment options for women and to decrease the stigma of mental illness. This project will educate at least 100 clinical researchers and clinicians on female-focused mental health research and treatment trends, while also disseminating educational information about mental health to more than a million women of all ages. Through this initiative, ADAA will reduce the stigma of mental illness, connect women to specialized treatment, and foster dialogue between women’s mental health researchers, clinicians, patients, and the public at large.